{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/AVR.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVR.AU\",,,,,undefined,":{"symbol":"AVR.AU","market":"AU","secType":"STK","nameCN":"ANTERIS TECHNOLOGIES LTD","latestPrice":4.58,"timestamp":1744870320000,"preClose":5.03,"halted":0,"volume":43589,"delay":0,"nameEN":"ANTERIS TECHNOLOGIES LTD","floatShares":27479674,"shares":36062087,"eps":-5.871535565929655,"marketStatus":"Not Yet Opened","change":-0.45,"latestTime":"04-17 16:12:00 AEST","open":4.99,"high":4.99,"low":4.55,"amount":207595,"amplitude":0.087475,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.871535565929655,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":5.03,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":1.5588321521477513,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVR.AU\",,,,,undefined,":{"symbol":"AVR.AU","floatShares":27479674,"roa":"-88.08%","roe":"-186.24%","lyrEps":-5.871536,"volumeRatio":1.5588321521477513,"shares":36062087,"dividePrice":0,"high":4.99,"amplitude":0.087475,"preClose":5.03,"low":4.55,"week52Low":4.26,"pbRate":"1.69","psRate":"39.20","week52High":23.45,"institutionHeld":0,"latestPrice":4.58,"eps":-5.871535565929655,"divideRate":0,"volume":43589,"delay":0,"ttmEps":-5.871535565929655,"open":4.99,"prevYearClose":8.27,"prevWeekClose":4.58,"prevMonthClose":6.5,"prevQuarterClose":6.5,"fiveDayClose":5.4,"twentyDayClose":9.93,"sixtyDayClose":9.25},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AVR.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVR.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523314249","title":"Anteris Technologies Says Over 100 Patients Treated with Aortic Stenosis Medical Device; Shares Down 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2523314249","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523314249?lang=en_us&edition=fundamental","pubTime":"2025-03-31 09:22","pubTimestamp":1743384148,"startTime":"0","endTime":"0","summary":"Anteris Technologies  said its biomimetic DurAVR transcatheter heart valve  has been used to treat over 100 patients worldwide, according to a Monday filing with the Australian bourse.Among the patients, 65 completed the primary endpoint measures of safety and efficacy, the filing said.The company plans to begin the DurAVR THV pivotal trial in the third quarter of the year, awaiting US Food and Drug Administration approval, per the filing.Shares were down 6% in morning trade on Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVR.AU","BK7126","BK7007"],"gpt_icon":0},{"id":"2521411656","title":"Anteris Technologies Reports Positive One-Year Results for Patients Treated with Transcatheter Heart Valve System","url":"https://stock-news.laohu8.com/highlight/detail?id=2521411656","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521411656?lang=en_us&edition=fundamental","pubTime":"2025-03-21 08:53","pubTimestamp":1742518392,"startTime":"0","endTime":"0","summary":"Anteris Technologies  said that one-year results for patients treated with its proprietary, balloon expandable, DurAVR Transcatheter Heart Valve system showed sustained \"excellent\" effective orifice area, low mean gradients, and zero prosthesis-patient mismatch small annuli patients, according to a Friday Australian bourse filing.The DurAVR THV demonstrated a favorable hemodynamic profile sustained to one-year. No valve or cardiovascular-related mortality was reported.Current commercial devices demonstrated prosthesis-patient mismatch rates of between 11.2% to 35.3%, a predictor of valve failure and disease progression.The one-year data builds on the existing clinical evidence and will be included in the planned Investigational Device Exemption submission to the US Food and Drug Administration to seek approval to conduct a DurAVR THV randomized, global pivotal study.A total of 65 patients completed the primary endpoint measure at 30 days.Its shares slid 2% in early trading on Friday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVR.AU","BK7126","BK7007"],"gpt_icon":0},{"id":"2520845848","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2520845848","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520845848?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:42","pubTimestamp":1742470946,"startTime":"0","endTime":"0","summary":"OptiNose (OPTN) shares soared 58% pre-bell Thursday after the company said overnight it agreed to a $330 million takeover by Paratek Pharmaceuticals.ProAssurance (PRA) shares surged 49% after the comp","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4107","BK7007","BK4082","PRA","AVR","BK7126","AVR.AU","OPTN","BK4007"],"gpt_icon":0},{"id":"2514288329","title":"Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2514288329","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514288329?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:00","pubTimestamp":1740747600,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS and BRISBANE, Australia, Feb. 28, 2025  -- Anteris Technologies Global Corp.   a structural heart company developing DurAVRTHV, a first-in-class, biomimetic, balloon expandable heart valve, is pleased to advise that Chief Executive Officer, Wayne Paterson will be presenting at both the 45th Annual TD Cowen Healthcare Conference, and the Barclays 27th Annual Global Healthcare Conference.The details of each conference and how to access them are as follows:. Fireside chat with analyst, Joshua Jennings, and 1x1 meetings. Anteris’ lead product, the DurAVR Transcatheter Heart Valve , was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood fl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anteris-present-healthcare-investor-conferences-130000956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4566","BK4137","BK7007","HCSG","BK4082","BK4207","TD","AVR.AU","BK7126","BK4585","COWN","BK4127","AVR"],"gpt_icon":0}],"pageSize":4,"totalPage":11,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-12-11","symbol":"AVR.AU","reason":null,"defaultRemindTime":1733871600000,"announcedDate":"2024-09-05","type":"delisting","dateTimestamp":1733835600000},{"market":"AU","date":"2024-10-15","symbol":"AVR.AU","reason":null,"defaultRemindTime":1728946800000,"announcedDate":"2024-09-05","type":"delisting","dateTimestamp":1728910800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVR.AU\",market:\"AU\",,,undefined,":[]}}